Group 1 - The core point of the news is that Hualan Vaccine's stock is currently trading at 24.01 yuan, reflecting a decline of 5.40% and is in a state of breaking its initial public offering price [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext on February 18, 2022, with an initial public offering price of 56.88 yuan per share and a total of 40.01 million shares issued [1] - The stock reached its highest point of 79.78 yuan on the first day of trading but has since experienced a downward trend [1] Group 2 - The total amount raised from the initial public offering was 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [1] - The actual funds raised were 251 million yuan less than the planned amount of 2.495 billion yuan, which was intended for various vaccine development and production projects [1] - The total issuance costs amounted to 31.5657 million yuan, with Huatai United Securities receiving a total of 22 million yuan in underwriting and sponsorship fees [1] Group 3 - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Core Points - Hualan Vaccine's stock closed at 19.55 yuan, down 2.98%, currently in a broken state [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext on February 18, 2022, with an initial public offering (IPO) price of 56.88 yuan per share [1][2] - The total amount raised from the IPO was 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs [2] Fundraising and Projects - The company initially planned to raise 2.495 billion yuan, with funds allocated for various vaccine development projects, including influenza, rabies, and pneumonia vaccines [2] - The total issuance costs amounted to 31.5657 million yuan, with the underwriter, Huatai United Securities, receiving 22 million yuan in underwriting and sponsorship fees [2] Dividend Distribution - On May 30, 2023, Hualan Vaccine announced a dividend distribution plan for 2022, proposing a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 5 shares for every 10 shares [2]

Group 1 - The company plans to distribute a cash dividend of 6 yuan per 10 shares, totaling approximately 357 million yuan, based on a total of 595,000,033 shares [3][35][40] - The profit distribution plan has been approved by the board and will be submitted for shareholder approval [36][41] - The company reported a net profit of approximately 20.8 million yuan for the first half of 2025, with available profits for distribution amounting to approximately 2.19 billion yuan [38][40] Group 2 - The company has appointed Chen Zhenbo as the new sponsor representative for ongoing supervision, replacing the previous representative due to internal job changes [8][9] - The company will hold its second extraordinary general meeting of 2025 on September 22, 2025, with both on-site and online voting options available for shareholders [11][12][13] Group 3 - The company has effectively managed its fundraising, with approximately 1.31 billion yuan utilized from the total raised amount of approximately 2.28 billion yuan [48][49] - The remaining balance of unused funds is approximately 1.05 billion yuan, with a portion invested in financial products [49][50] - The company has established a special account for managing the raised funds, ensuring compliance with regulatory requirements [50][51]

中国经济网北京8月5日讯华兰疫苗（301207）(301207.SZ)今日收报18.87元，跌幅1.15%。 华兰疫苗于2022年2月18日在深交所创业板上市，公开发行的股票数量为4001.00万股，发行价格为56.88 元/股，保荐机构(主承销商)为华泰联合证券有限责任公司，保荐代表人为贾鹏、刘晓宁。 华兰疫苗首次公开发行股票的发行费用总额为3156.57万元，其中，华泰联合证券有限责任公司获得承 销费用、保荐费用合计2200.00万元。 2023年5月30日，华兰疫苗发布2022年年度权益分派实施公告。公司2022年年度权益分派方案为：以公 司现有总股本400,010,000股为基数，向全体股东每10股派3.00元人民币现金，同时，以资本公积金向全 体股东每10股转增5股。本次权益分派股权登记日为2023年6月6日，除权除息日为2023年6月7日。 华兰疫苗首次公开发行股票募集资金总额为22.76亿元，扣除含税发行费用3156.57万元，实际募集资金 净额为22.44亿元。华兰疫苗此次募集资金比原计划少2.51亿元，公司2021年11月12日披露招股书注册稿 显示，公司拟募集资金24.95亿元，分别用于流 ...